Citomix Pellet
NDC Package 17089-076-20
Package Information
Citomix (aldesleukin - binetrakin - canakinumab - centella asiatica - cranberry - human interleukin-6 (nonglycosylated) - interferon gamma-1b - lenograstim - pineapple - sus scrofa bone marrow - sus scrofa small intestine mucosa lymph follicle - sus scrofa thymus -) pellets is take 15 minutes before mealsAdults and children 12 years and older 5 pellets 3 times per dayChildren between 12 years and 6 years of age 3 pellets 3 times per dayChildren under 6 years 1 pellet 3 times per day to be dissolved into a little water. This formulation utilizes a pellet delivery system. Marketed by Guna Spa, this product is identified by NDC 17089-076.
Identification & Billing
Clinical Specifications
- ALDESLEUKIN 5 [hp_C]/4g
- BINETRAKIN 4 [hp_C]/4g
- CANAKINUMAB 5 [hp_C]/4g
- CENTELLA ASIATICA 3 [hp_X]/4g
- CRANBERRY 3 [hp_X]/4g
- HUMAN INTERLEUKIN-6 (NONGLYCOSYLATED) 7 [hp_C]/4g
- INTERFERON GAMMA-1B 4 [hp_C]/4g
- LENOGRASTIM 4 [hp_C]/4g
- PINEAPPLE 3 [hp_X]/4g
- SUS SCROFA BONE MARROW 4 [hp_C]/4g
- SUS SCROFA SMALL INTESTINE MUCOSA LYMPH FOLLICLE 4 [hp_C]/4g
- SUS SCROFA THYMUS 4 [hp_C]/4g
- Allergens - [CS]
- Allergens - [CS]
- Cell-mediated Immunity - [PE] (Physiologic Effect)
- Dietary Proteins - [CS]
- Fruit Proteins - [EXT]
- Increased Histamine Release - [PE] (Physiologic Effect)
- Increased Lymphocyte Activation - [PE] (Physiologic Effect)
- Increased Lymphocyte Cell Production - [PE] (Physiologic Effect)
- Interferon gamma - [EPC] (Established Pharmacologic Class)
- Interferon-gamma - [CS]
- Interleukin-2 - [CS]
- Lymphocyte Growth Factor - [EPC] (Established Pharmacologic Class)
- Non-Standardized Food Allergenic Extract - [EPC] (Established Pharmacologic Class)
- Non-Standardized Plant Allergenic Extract - [EPC] (Established Pharmacologic Class)
- Plant Proteins - [CS]
Regulatory & Marketing
Hierarchy Structure
- 17089 - Guna Spa
- 17089-076 - Citomix
- 17089-076-20 - 2 TUBE in 1 BOX / 4 g in 1 TUBE
- 17089-076 - Citomix
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 17089-076-20 identifies a specific commercial package of 2 tube in 1 box / 4 g in 1 tube of Citomix, a human over the counter drug labeled by Guna Spa. This pellet is formulated for oral use and contains aldesleukin; binetrakin; canakinumab; centella asiatica; cranberry; human interleukin-6 (nonglycosylated); interferon gamma-1b; lenograstim; pineapple; sus scrofa bone marrow; sus scrofa small intestine mucosa lymph follicle; sus scrofa thymus as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Guna Spa on May 23, 2006. The current certification is valid through December 31, 2026.
How is this Guna Spa product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 17089007620. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.